dacomitinib
Also known as PF-00299804, PF 00299804-03, PF-00299804-03, dacomitinib anhydrous
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.
Key facts
- Drug.ChemSpiderID
- 9685914
- Drug.image
- Dacomitinib.svg
- Drug.image_class
- skin-invert-image
- Drug.pronounce
- dak" oh mi' ti nib
- Drug.tradename
- Vizimpro
- Drug.MedlinePlus
- a618055
- Drug.DailyMedID
- Dacomitinib
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EB07
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
~4 min read
Article
3 sectionsContents
- Synthesis
- References
- External links
{{Infobox drug | image = Dacomitinib.svg | image_class = skin-invert-image | alt = | caption =
| pronounce = dak" oh mi' ti nib | tradename = Vizimpro | Drugs.com = | MedlinePlus = a618055 | DailyMedID = Dacomitinib | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = L01 | ATC_suffix = EB07